Cipla to launch cheap generic version of Tamiflu in Mexico
Generic drugmaker Cipla is to launch a cheaper copy version of Swiss drug major Roche's Tamiflu (oseltamivir) in Mexico, the country in which the recent swine flu outbreak started. The Mumbai, India-based company is to sell the drug, to be called Antiflu, for 10 euros ($13.63) per course of treatment as compared to Tamiflu, which costs governments 15 euros and is sold for 12 euros in poorer countries. Roche and partner Gilead would not confirm whether they would undertake legal action against Cipla when asked by the UK Financial Times, but noted they were in negotiations with the government of Mexico regarding the matter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze